Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
BTIG Reiterates Neutral Rating on Shattuck Labs (STTK)
July 1, 2024 4:47 PM EDTBTIG analyst Kaveri Pohlman reiterated a Neutral rating on Shattuck Labs (NASDAQ: STTK).
The analyst comments "We believe that the EHA update showed encouraging efficacy that could translate into meaningful improvement in survival. However, the updates from other CD47-targeting programs, Gileads (GILD, Not Rated) and ALX Oncologys (ALXO, Not Rated), suggest that randomized trial data is needed to define the benefit of adding CD47 and CD40 targeting drugs to azacitidine monotherapy. This is because SL-172154s ORR and CR rates for 1L TP53 mutant AML and HR-MDS look comparable with... More
